Minimal residual disease in leukaemia patients

Lancet Oncology

Volumn 2, Issue 7, 2001, Pages 409-417

  Szczepański, Tomasz ^a,b   Orfão, Alberto ^c,d   Van Der Velden, Vincent H J ^a,c   San Miguel, Jésus F ^c   Van Dongen, Jacques J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CHILD; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; METHODOLOGY; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ADULT; CHILD; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 0035411192     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00418-6     Document Type: Review

References (47)

1. Campana D., Pui C.H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 85:1995;1416-1434.
2. Van Dongen J.J.M., Szczepanski T., de Bruijn M.A.C., et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther. 2:1996;121-133.
3. Lucio P., Parreira A., van den Beemd M.W., et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B- ALL. Leukemia. 13:1999;419-427.
4. Porwit-MacDonald A., Bjorklund E., Lucio P., et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia. 14:2000;816-825.
5. Van den Beemd M.W.M., Boor P.P.C., Van Lochem E.G., et al. Flow ctometric analysis of the Vß repertoire in healthy controls. Cytometry. 40:2000;336-345.
6. Brinkman K., van Dongen J.J.M., van Lom K., et al. Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vbeta antibodies. Leukemia. 12:1998;150-154.
7. Langerak A.W., van den Beemd M.W.M., Wolvers-Tettero I.L.M., et al. Molecular and flow cytometric analysis of the Vß repertoire for clonality assessment in mature TCRαß T-cell proliferatons. Blood. 98:2000;165-172.
8. + T cell acute lymphoblastic leukemia. Leukemia. 13:1999;206-214.
9. Van Wering E.R., Beishuizen A., Roeffen E.T., et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia. 9:1995;1523-1533.
10. Macedo A., San Miguel J.F., Vidriales M.B., et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol. 49:1996;15-18.
11. Campana D., Coustan Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 38:1999;139-152.
12. Pongers-Willemse M.J., Seriu T., Stolz F., et al. Primers and protocols for standardized MRD detection in ALL using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia. 13:1999;110-118.
13. Van Dongen J.J.M., Macintyre E.A., Gabert J.A., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 13:1999;1901-1928.
14. Van der Velden V.H.J., Schoch C., Langerak A.W., et al. Low frequency of RT-PCR-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease. Br J Haematol. 113:2001;1082-1083.
15. Sykes P.J., Neoh S.H., Brisco M.J., et al. Quantitation of targets for PCR by use of limiting dilution. Biotechniques. 13:1992;444-449.
16. Cross N.C., Feng L., Chase A., et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 82:1993;1929-1936.
17. Pongers-Willemse M.J., Verhagen O.J.H.M., Tibbe G.J.M., et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional regions specific TaqMan probes. Leukemia. 12:1998;2006-2014.
18. Verhagen O.J., Willemse M.J., Breunis W.B., et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia. 14:2000;1426-1435.
19. Brisco M.J., Condon J., Hughes E., et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet. 343:1994;196-200.
20. Coustan-Smith E., Behm F.G., Sanchez J., et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 351:1998;550-554.
21. Cave H., van der Werff ten Bosch J., Suciu S., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 339:1998;591-598.
22. Van Dongen J.J.M., Seriu T., Panzer-Grumayer E.R., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 352:1998;1731-1738.
23. Coustan-Smith E., Sancho J., Hancock M.L., et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 96:2000;2691-2696.
24. Ciudad J., San Miguel J.F., Lopez-Berges M.C., et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol. 16:1998;3774-3781.
25. Knechtli C.J., Goulden N.J., Hancock J.P., et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 92:1998;4072-4079.
26. Hochhaus A., Weisser A., La Rosee P., et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia. 14:2000;998-1005.
27. Paschka P., Schoch C., Lahaye T., et al. Monitoring the response of CML patients treated with STI571 by molecular cytogenetics and quantitative RT-PCR. Blood. 96:2000;734. Abstr.
28. Van Rhee F., Lin F., Cross N.C., et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 14:1994;609-612.
29. Cross N.C. Minimal residual disease in chronic myeloid leukaemia. Hematol Cell Ther. 40:1998;224-228.
30. Raanani P., Dazzi F., Sohal J., et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 99:1997;945-950.
31. Diverio D., Rossi V., Avvisati G., et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood. 92:1998;784-789.
32. Lo Coco F., Diverio D., Avvisati G., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 94:1999;2225-2229.
33. Reading C.L., Estey E.H., Huh Y.O., et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 81:1993;3083-3090.
34. San Miguel J.F., Martinez A., Macedo A., et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 90:1997;2465-2470.
35. Venditti A., Buccisano F., Del Poeta G., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 96:2000;3948-3952.
36. Vidriales M.B., Lopez-Berges M.C., Diaz-Mediavilla J., et al. Early immunophenotypical evaluation of minimal residual disease (MRD) in AML identifies different risk-groups of patients, and can contribute to post-induction treatment stratification. Blood. 96:2000;544. Abstr.
37. Nucifora G., Larson R.A., Rowley J.D. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 82:1993;712-715.
38. Satake N., Maseki N., Kozu T., et al. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br J Haematol. 91:1995;892-898.
39. Hebert J., Cayuela J.M., Daniel M.T., et al. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood. 84:1994;2291-2296.
40. Tobal K., Johnson P.R., Saunders M.J., et al. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol. 91:1995;104-108.
41. Krauter J., Wattjes M.P., Nagel S., et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol. 107:1999;80-85.
42. Schultze J.L., Donovan J.W., Gribben J.G. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med. 77:1999;259-565.
43. Corradini P., Ladetto M., Pileri A., Tarella C. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies. Leukemia. 13:1999;1691-1695.
44. Lopez-Guillermo A., Cabanillas F., McLaughlin P., et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 91:1998;2955-2960.
45. Finke J., Slanina J., Lange W., Dolken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol. 11:1993;1668-1673.
46. Limpens J., Stad R., Vos C., et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood. 85:1995;2528-2536.
47. Jacquy C., Lambert F., Soree A., et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging? Bone Marrow Transplant. 23:1999;681-686.